Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis: 2years of entecavir treatment
- Authors
- Shin, Seung Kak; Kim, Jeong Han; Park, Hyeonsu; Kwon, Oh Sang; Lee, Hyun Jung; Yeon, Jong Eun; Byun, Kwan Soo; Suh, Sang Jun; Yim, Hyung Joon; Kim, Yun Soo; Kim, Ju Hyun
- Issue Date
- Dec-2015
- Publisher
- Blackwell Publishing Inc.
- Keywords
- entecavir; hepatitis B virus; liver fibrosis; liver function
- Citation
- Journal of Gastroenterology and Hepatology, v.30, no.12, pp 1775 - 1781
- Pages
- 7
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Journal of Gastroenterology and Hepatology
- Volume
- 30
- Number
- 12
- Start Page
- 1775
- End Page
- 1781
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7281
- DOI
- 10.1111/jgh.13020
- ISSN
- 0815-9319
1440-1746
- Abstract
- Background and Aim
Entecavir (ETV) induces biochemical and histologic improvement of the liver in patients with chronic hepatitis B. This study aimed to confirm that 2 years of ETV treatment improves liver function and non-invasive fibrosis markers in patients with hepatitis B virus (HBV)-associated cirrhosis.
Methods
A total 472 naïve patients with HBV-associated cirrhosis was treated with ETV for at least 2 years, between March 2007 and December 2012. Model for end-stage liver disease and Child-Pugh (CP) score were used to evaluate the improvement of liver function. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index were used to evaluate the improvement of fibrosis.
Results
The final 370 of 472 patients with HBV-associated cirrhosis were enrolled. Mean age was 51 ± 10 years, and 240 patients (64.9%) were men. The distribution of CP class was 71.1% in A, 24.6% in B, and 4.3% in C. Mean end-stage liver disease and CP score changed over the study period from 8.5 ± 4.6 to 6.2 ± 4.2 (P < 0.001) and from 6.2 ± 1.6 to 5.6 ± 0.9 (P < 0.001), respectively. Aspartate transaminase to platelet ratio index, FIB-4 index, and fibrosis index changed from 3.6 ± 4.5 to 1.5 ± 1.5 (P < 0.001), from 7.0 ± 6.2 to 3.9 ± 2.8 (P < 0.001), and from 3.3 ± 0.9 to 2.5 ± 1.1 (P < 0.001), respectively.
Conclusions
After 2 years of treatment, ETV improves liver function and non-invasive fibrosis markers in patients with HBV-associated cirrhosis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.